Skip to Content

Commit (nicotine) Disease Interactions

There are 4 disease interactions with Commit (nicotine):

Major

Nicotine (Includes Commit) ↔ Cvd/Pvd

Severe Potential Hazard, Moderate plausibility

Applies to: Ischemic Heart Disease, Peripheral Arterial Disease, Arrhythmias

Nicotine has dose-dependent cardiovascular effects. At dosages used for smoking cessation, nicotine may produce peripheral vasoconstriction and increase heart rate, myocardial contractility and blood pressure. Although these effects are relatively minor and clinically insignificant in most healthy individuals, complications may occasionally occur in patients with underlying cardiovascular disease, particularly if they continue to smoke during nicotine therapy. Therapy with nicotine should be administered cautiously in patients with coronary artery disease, cardiac arrhythmias, and peripheral vascular disease. In general, nicotine therapy should be avoided during the immediate postmyocardial infarction period, in severe or worsening angina, and in life-threatening arrhythmias. All patients should stop smoking completely during nicotine replacement therapy.

References

  1. Warner JG, Little WC "Myocardial infarction in a patient who smoked while wearing a nicotine patch." Ann Intern Med 120 (1994): 695
  2. Rennard S, Daughton D, Cheney R, Thompson A, Miles R, Windle J, Repsher L, Clifford DP, Schones W, Fortmann SP, Killen JD, Pe "Nicotine replacement therapy for patients with coronary artery disease." Arch Intern Med 154 (1994): 989-95
  3. "Product Information. Nicorette (nicotine)." SmithKline Beecham, Philadelphia, PA.
  4. "Product Information. Habitrol (nicotine)." Basel Pharmaceuticals, Summit, NJ.
  5. Khosla S, Laddu A, Ehrenpreis S, Somberg JC "Cardiovascular effects of nicotine: relation to deleterious effects of cigarette smoking." Am Heart J 127 (1994): 1669-72
View all 5 references
Major

Nicotine (Includes Commit) ↔ Pheochromocytoma

Severe Potential Hazard, Moderate plausibility

Applies to: Pheochromocytoma

Nicotine causes the release of catecholamines from the adrenal medulla. Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas. Therapy with nicotine should be administered cautiously in patients with these tumors.

References

  1. "Product Information. Nicorette (nicotine)." SmithKline Beecham, Philadelphia, PA.
  2. "Product Information. Habitrol (nicotine)." Basel Pharmaceuticals, Summit, NJ.
  3. "Product Information. Nicotrol NS (nicotine)." McNeil Pharmaceutical, Raritan, NJ.
Moderate

Nicotine (Includes Commit) ↔ Hyperthyroidism

Moderate Potential Hazard, Moderate plausibility

Applies to: Hyperthyroidism

Nicotine causes the release of catecholamines from the adrenal medulla, which can exacerbate the sympathetic nervous system manifestations of hyperthyroidism such as tachycardia, angina, and heart failure. Therapy with nicotine should be administered cautiously in patients with hyperthyroidism.

References

  1. "Product Information. Nicorette (nicotine)." SmithKline Beecham, Philadelphia, PA.
  2. "Product Information. Habitrol (nicotine)." Basel Pharmaceuticals, Summit, NJ.
Moderate

Nicotine (Includes Commit) ↔ Liver Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Nicotine is primarily metabolized by the liver, and systemic clearance is dependent on liver blood flow. Although data are lacking, impairment of liver function is likely to reduce nicotine clearance to some extent. Patients with liver disease using a nicotine product should be monitored for development of undue adverse effects and signs of nicotine toxicity, including nausea, salivation, cold sweat, palpitation, abdominal pain, diarrhea, headache, dizziness, vomiting, auditory and vision disturbances, tremors, mental confusion, and weakness. If necessary, nicotine dosage should be reduced or the treatment discontinued.

References

  1. "Product Information. Habitrol (nicotine)." Basel Pharmaceuticals, Summit, NJ.
  2. Neurath GB "Aspects of the oxidative metabolism of nicotine." Clin Investig 72 (1994): 190-5
  3. "Product Information. Nicorette (nicotine)." SmithKline Beecham, Philadelphia, PA.
  4. "Product Information. Nicotrol NS (nicotine)." McNeil Pharmaceutical, Raritan, NJ.
  5. "Product Information. NicoDerm CQ (nicotine)." SmithKline Beecham, Philadelphia, PA.
  6. Benowitz NL, Jacob P, Fong I, Gupta S "Nicotine metabolic profile in man - comparison of cigarette smoking and transdermal nicotine." J Pharmacol Exp Ther 268 (1994): 296-303
View all 6 references

Commit (nicotine) drug Interactions

There are 56 drug interactions with Commit (nicotine)

Commit (nicotine) alcohol/food Interactions

There is 1 alcohol/food interaction with Commit (nicotine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide